Design and synthesis of dual inhibitors of HIV reverse transcriptase and integrase: Introducing a diketoacid functionality into delavirdine

Research output: Contribution to journalArticlepeer-review

38 Scopus citations

Abstract

Cost and toxicity problems associated with highly active antiretroviral therapy (HAART) in HIV/AIDS treatment could be alleviated by using designed multiple ligands (DMLs). Dual inhibitors of HIV reverse transcriptase (RT) and integrase (IN) were rationally designed by introducing a diketoacid (DKA) functionality into the tolerant C-5 site of RT inhibitor delavirdine. The resulting compounds all demonstrate good activity against both RT and IN in enzymatic assays and HIV in cell-based assay, whereas their C-7 regioisomers are all inactive in these assays. Balanced activities were observed with C-3 halogenated inhibitors.

Original languageEnglish (US)
Pages (from-to)3587-3595
Number of pages9
JournalBioorganic and Medicinal Chemistry
Volume16
Issue number7
DOIs
StatePublished - Apr 1 2008

Keywords

  • Dual inhibitors
  • HIV
  • Integrase
  • Reverse transcriptase

Fingerprint Dive into the research topics of 'Design and synthesis of dual inhibitors of HIV reverse transcriptase and integrase: Introducing a diketoacid functionality into delavirdine'. Together they form a unique fingerprint.

Cite this